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Childhood onset systemic lupus
erythematosus
a  b  s  t  r  a  c  t
Objective: To evaluate alcohol, smoking and/or illicit drug use, and history of bullying in
adolescent childhood-onset systemic lupus erythematosus and healthy controls.
Methods: 174 adolescents with pediatric rheumatic diseases were selected. All of the 34
childhood-onset systemic lupus erythematosus patients and 35 healthy controls partici-
pated  in this study. A cross-sectional study included demographic/anthropometric data and
puberty markers assessments; structured questionnaire and CRAFFT screening interview.
Results: McNemar tests indicated an excellent test–retest reliability of the structured ques-
tionnaire (p = 1.0). The median current age was similar between childhood-onset systemic
lupus erythematosus patients and controls [15 (12–18) vs. 15 (12–18) years, p = 0.563]. The
median of menarche age was signiﬁcantly higher in childhood-onset systemic lupus erythe-
matosus patients compared to controls [12 (10–15) vs. 11.5 (9–15) years, p = 0.041], particularly
in  those that lupus had occurred before ﬁrst menstruation [13 (12–15) vs. 11.5(9–15) years,
p  = 0.007]. The other puberty marker and sexual function parameters were similar in both
groups (p > 0.05). Alcohol use was similar in both childhood-onset systemic lupus erythe-
matosus patients and controls (38% vs. 46%, p = 0.628). A trend of lower frequency of CRAFFT
score  ≥2 (high risk for substance abuse/dependence) was evidenced in childhood-onset sys-
temic lupus erythematosus patients compared to controls (0% vs. 15%, p = 0.053). Bullyingwas  reported similarly for the two groups (43% vs. 44%, p = 0.950). Further analysis in lupus
patients regarding alcohol/smoking/illicit drug use showed no differences in demographic
data, puberty markers, history of bullying, sexual function, contraceptive use, disease activ-
ity/damage scores, clinical/laboratorial features and treatments (p > 0.05).∗ Corresponding author.
E-mail: clovisaasilva@gmail.com (C.A. Silva).
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Conclusion: This study showed high frequencies of early alcohol use in lupus adolescents
and  healthy controls, despite of a possible low risk for substance abuse/dependence in
childhood-onset systemic lupus erythematosus patients.
© 2016 Elsevier Editora Ltda. All rights reserved.
Uso  de  álcool,  tabaco  e  drogas  ilícitas  por  pacientes  com  lúpus






Lúpus eritematoso sistêmico de
início na infância
r  e  s  u  m  o
Objetivo: Avaliar o uso de álcool, tabaco e/ou drogas ilícitas e a história de bully-
ing  entre adolescentes com lúpus eritematoso sistêmico pediátrico (LES-p) e controles
saudáveis.
Métodos: Selecionaram-se 174 adolescentes com doenc¸as reumatológicas pediátricas. Todos
os  34 pacientes com LES-i e 35 controles saudáveis participaram deste estudo. Um estudo
transversal incluiu avaliac¸ões de dados demográﬁcos/antropométricos e marcadores da
puberdade, um questionário estruturado e a entrevista de triagem Crafft.
Resultados: Testes de McNemar indicaram uma excelente conﬁabilidade teste-reteste do
questionário estruturado (p = 1,0). A mediana da idade atual foi semelhante entre pacientes
com  LES-i e controles [15 (12 a 18) vs. 15 (12 a 18) anos, p = 0,563]. A mediana da idade na
menarca foi signiﬁcativamente maior em pacientes com LES-i em comparac¸ão com os con-
troles  [12 (10 a 15) vs. 11,5 (9 a 15) anos, p = 0,041], particularmente naquelas em quem o
lúpus ocorreu antes da primeira menstruac¸ão [13 (12 a 15) vs. 11,5 (9 a 15) anos, p = 0,007].
Os  outros marcadores da puberdade e parâmetros de func¸ão sexual foram similares nos
dois grupos (p > 0,05). O uso de álcool foi semelhante entre pacientes com LES-i e controles
(38% vs. 46%, p = 0,628). Evidenciou-se uma tendência de menor frequência de pontuac¸ão ≥
2  no Crafft (alto risco para uso abusivo/dependência de substâncias) em pacientes com LES-i
em  comparac¸ão com os controles (0% vs. 15%, p = 0,053). O bullying foi relatado em frequên-
cia semelhante nos dois grupos (43% vs. 44%, p = 0,950). Uma  análise mais aprofundada
em  relac¸ão ao uso de álcool/tabaco/drogas ilícitas em pacientes com lúpus não mostrou
diferenc¸as  nos dados demográﬁcos, marcadores da puberdade, história de bullying, func¸ão
sexual, uso de anticoncepcionais, escores de atividade/danos da doenc¸a, características
clínicas/laboratoriais e tratamentos (p > 0,05).
Conclusão: Este estudo mostrou uma alta frequência de uso precoce de álcool em ado-
lescentes com lúpus e controles saudáveis, apesar de um possível baixo risco para uso
abusivo/dependência de substâncias em pacientes com LES-i.















were followed at the Pediatric Rheumatology Unit of Hospitalntroduction
hildhood-onset systemic lupus erythematosus (c-SLE) is
 rare disease that occurs mainly in adolescents. Adoles-
ence is a transitional period of physical and psycholog-
cal development that may be associated with high-risk
ehaviors.1
In this regard, alcohol, smoking and illicit drug use
s a relevant public health issue in healthy adolescents
ith high risk for substance abuse/dependence2 and sex-
al dysfunction.3 Furthermore, adolescents may suffer from
ullying victimization with poorer health status and psycho-
ogical distress.4 However, the concomitant assessment of
hese adolescent health problems was not performed in c-SLE
opulation.
Therefore, the objective of our study was to assess alcohol,
moking and/or illicit drug use in adolescent c-SLE patientsand healthy controls. We  also evaluated the possible associ-
ations between alcohol, smoking and/or illicit drug use and:
demographic data, bullying, clinical features, puberty mark-
ers, sexual function, contraceptive use, disease parameters
and treatments in lupus population.
Materials  and  methods
Patients  and  controls
From February to June 2014, 174 adolescents (current age vary-
ing from 10 to 19 years according to World Health Organization
criteria for adolescents) with pediatric rheumatic diseasesdas Clínicas da Faculdade de Medicina da Universidade de São
Paulo, Brazil. Out of them, 34 adolescents had c-SLE. The exclu-
sion criteria were current psychiatric disorders or unwilling
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to participate. All of them participated in this cross-sectional
study and fulﬁlled the American College of Rheumatology
classiﬁcation criteria for SLE.5 The control group included
35 healthy female adolescents followed-up in our University
Hospital at the educational and preventive group of the Ado-
lescent Unit. These control volunteers were subjected to the
same exclusion criteria. Local Ethics Committee of our univer-
sity hospital approved this study.
Puberty  markers,  sexual  function  and
alcohol/smoking/illicit  drug  use,  and  bullying
This study included demographic/anthropometric data and
puberty markers assessments; a structured questionnaire
evaluated sexual function and alcohol, smoking and illicit
drug use, bullying and the Portuguese CRAFFT (mnemonic
acronym of car, relax, alone, forget, friends, trouble)
screen (CRAFFT/CEASER) version.6,7 These aspects were
performed blinded to clinical, laboratorial and treatment
assessments.
Socio-demographic  and  anthropometric  data
Current age, gender, years of education, weight and
height were evaluated. Body mass index (BMI) was deﬁned
by the formula: weight in kilograms/height in square
meters.
The Brazilian socio-economic classes were classiﬁed
according to the ABEP (Associac¸a˜o Brasileira de Empresas de
Pesquisa).8
Puberty  markers  assessments
Secondary sexual characteristics were classiﬁed according to
Tanner pubertal changes in both genders.9 Age at ﬁrst men-
struation (menarche) and ﬁrst ejaculation (spermarche) were
registered based on memory  recollection.
Structured  questionnaire
A pilot study was carried out in 30 consecutive adolescents
who  were tested and then retested 1–2 months later in Febru-
ary and April 2014, to evaluate response reliability of the
aforementioned questionnaire, covering the following fea-
tures: sexual function and alcohol/smoking and illicit drugs
use.
Sexual function evaluation included: presence and age at
ﬁrst sexual intercourse, sexual intercourse in the last month,
use of male contraception (condom) in the ﬁrst sexual activity,
oral and emergency contraceptive use, knowledge of sexual
activity by parents and number of sexual partners in life.
Both healthy controls and c-SLE patients have a routine ori-
entation about sexual function and birth controls, emotional
problems and drugs issues in the Adolescent and Pediatric
Rheumatology Units of our University Hospital. Barrier meth-
ods are encouraged for our entire male and female sexually
active c-SLE patient. Although its long-term use is associated
with decreased bone mineral density, depot medroxyproges-
terone acetate injection (every three months administered
in our Day Hospital) is our preferable method indicated for 0 1 6;5 6(3):228–234
all sexually active c-SLE patient, due to adequate adher-
ence. Progestin-only pills may be also used, although the
main issue related to its use by adolescents is poor compli-
ance due to menstrual irregularity. Oral levonorgestrel is also
indicated as an emergency contraception method in female
c-SLE.
Alcohol/smoking and illicit drugs use assessment involved:
age at alcohol initiation, number of days of alcohol use in
the last 30 days, age at smoking initiation, number of days
using cigarettes in the last 30 days, age at illicit drug initi-
ation and number of days using illicit drugs in the last 30
days. Use of illicit inhalants drug (glue snifﬁng, aerosol and
solvent) and illegal drugs [marijuana, stimulants (cocaine,
crack and speed), LSD, opiates, heroin and ecstasy] were
systematically assessed. Bullying, which is deﬁned as recur-
rent exposure to emotional and/or physical aggression, was
registered based on memory  recollection. The questionnaire
was given in the absence of legal guardians, relatives and/or
friends.
CRAFFT  screening
The Portuguese version of physician-conducted CRAFFT
(CRAFFT/CEASER) screen was used and consists of 9 ques-
tions developed to screen adolescents for high-risk alcohol
and drugs use.6 This questionnaire is divided in two  parts.
Part A includes three questions regarding the use of alcohol,
marijuana, hashish or another substance in the last twelve
months. If the adolescent responded “no” to all three ques-
tions, only the question related to “Car” of the B-part should
be asked. If the adolescent answered “yes” to one of the open-
ing questions, all of the questions of part B should be asked.
The B-part contained six questions, which are signs of prob-
lematic substance use, such as: 1. “Have you ever ridden in a
car driven by someone (including yourself) who  was “high” or
had been using alcohol or drugs?”, 2. “Do you ever use alco-
hol or drugs to relax, feel better about yourself, or ﬁt in?”, 3.
“Do you ever use alcohol or drugs while you are by yourself,
or alone?”, 4 “Do you ever forget things you did while using
alcohol or drugs?”, 5. “Do your family or friends ever tell you
that you should cut down on your drinking or drug use?”, 6.
“Have you ever gotten into trouble while you were using alco-
hol or drugs?”. One point was related to each answer “yes”
in the B-part of the questionnaire. A total score of ≥2 indi-
cated high risk for substance abuse/dependence and a need
for additional assessment.7
c-SLE  clinical,  laboratorial  and  treatment  assessments
SLE clinical manifestations were deﬁned as: articular involve-
ment (non-erosive arthritis), mucocutaneous lesions (malar or
discoid rash, oral ulcers or photosensitivity), serositis (pleu-
ritis or pericarditis), neuropsychiatric diseases (seizure or
psychosis), renal involvement (proteinuria ≥0.5 g/24 h, pres-
ence of cellular casts, and/or persistent hematuria ≥10 red
blood cells per high power ﬁeld), and hematologic abnor-
malities (hemolytic anemia, leukopenia with a white blood
cell count <4000/mm3, lymphopenia <1500/mm3 on two  or
more occasions and thrombocytopenia with platelet count
<100,000/mm3 in the absence of drugs or infection).
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Erythrocyte sedimentation rate (ESR) was performed by
estergreen method and C-reactive protein (CRP) by neph-
lometry. Anti-double-stranded DNA (anti-dsDNA) autoan-
ibody was detected by indirect immunoﬂuorescence using
rithidia luciliae as substrate.
Disease activity was evaluated according to SLE Disease
ctivity Index 2000 (SLEDAI-2K).10 Cumulative damage was
easured by SLE International Collaborating Clinics/ACR
amage Index (SLICC/ACR-DI).11
Data concerning the use and current dosage of prednisone,
ydroxychloroquine, methotrexate, azathioprine, intravenous
yclophosphamide, mycophenolate mofetil and intravenous
mmunoglobulin were also determined.
tatistical  analysis
he test–retest reliability of the structured questionnaire was
eriﬁed using the McNemar test. Results were presented as
he mean ± standard deviation (SD) or median (range) for con-
inuous and number (%) for categorical variables. Data were
ompared by t test or Mann–Whitney test in continuous vari-
bles to evaluate differences between c-SLE and controls, and
etween SLE subgroups. For categorical variables, differences
ere assessed by Fisher’s exact test or Pearson chi-square test.
pearman rank correlation coefﬁcient was used for CRAFFT
core and age correlations. The level of signiﬁcance was set at
% (p < 0.05).
esults
cNemar tests indicated an excellent test–retest reliability of
he structured questionnaire (p = 1.0).
Table 1 includes demographic data, puberty markers, sex-
al function, alcohol, smoking and illicit drug use, and bullying
n c-SLE and controls. The median current age was simi-
ar between c-SLE patients and controls [15 (12–18) vs. 15
12–18) years, p = 0.563], likewise the frequency of female gen-
er (76% vs. 74%, p = 0.833). BMI  was signiﬁcantly higher in
-SLE patients compared to controls [22.11 (16.4–36.6) vs. 19.53
16.4–25.9) kg/m2, p = 0.002].
The median of menarche age was signiﬁcantly higher in
-SLE patients compared to controls [12 (10–15) vs. 11.5 (9–15)
ears, p = 0.041], particularly in those that lupus had occurred
efore menarche [13 (12–15) vs. 11.5 (9–15) years, p = 0.007]
Table 1).
The frequencies of alcohol, smoking and/or illicit drug use
ere high and similar in both c-SLE patients and controls (38%
s. 46%, p = 0.628). Marijuana was used by two healthy controls
nd none in c-SLE patients (0% vs. 6%, p = 1.000). The median
f CRAFFT score was alike in both groups [0 (0–1) vs. 0 (0–5),
 = 0.721], whereas a trend of lower frequency of CRAFFT score
2 was evidenced in c-SLE patients compared to controls (0%
s. 15%, p = 0.053). Bullying was reported similarly in the two
roups (43% vs. 36%, p = 0.572) (Table 1).
Further analysis of lupus patients that used alcohol, smok-
ng and/or illicit drug compared to those that did not use
hese substances showed no differences in demographic
ata, puberty markers, sexual function parameters, contra-
eptive use, history of bullying, lupus clinical manifestations, 6;5 6(3):228–234 231
SLEDAI-2 K, SLICC/ACR-DI, ESR, CRP and anti-dsDNA autoan-
tibodies (p > 0.05). Current use and current dose of prednisone,
hydroxychloroquine, methotrexate, azathioprine, intravenous
cyclophosphamide and mycophenolate mofetil were also sim-
ilar in both groups (p > 0.05).
No correlations were evidenced between CRAFFT score in
both c-SLE and healthy controls groups (n = 69) and: current
age (p = 0.249), age of alcohol onset (p = 0.800) and age onset of
sexual intercourse (p = 0.297).
Discussion
Our study showed high frequencies of early alcohol use in
adolescents with c-SLE and in healthy controls, despite of
a possible low risk for substance abuse/dependence in the
former group.
The major advantage of this study was the assessment
of a structured questionnaire with high test–restest reliabil-
ity that evaluated sexual function, licit and illicit substance
use and bullying. CRAFFT score, which is a screening tool for
high-risk alcohol or drugs use in teenagers, was also applied.12
Furthermore, a healthy control group with similar age, gen-
der and socio-economic class was relevant, since these data
were associated with bullying, alcohol and illicit drugs in
adolescents.2,12–15 However, the major limitations of this study
were the small number of subjects recruited in only one Pedi-
atric Rheumatic service, a cross sectional design and non use
of a standardized self-completion questionnaire for different
types of bullying.4 In addition, there was no sample size cal-
culation for this study, which does not allow generalizing of
these results, especially in a research that was based only on
the questionnaire and not for medical tests or a more  detailed
history.
Alcohol consumption was high in the present study, as
expected in adolescents with c-SLE and healthy controls.
Prevalence of alcohol use in adolescents varied from 23%
to 68%, using distinct methodological procedures, such as
questionnaires or structured interviews.14,16 This ﬁnding is
probably related to low-cost and easy access to adolescents
in our country, in spite the efforts of Brazilian healthy pub-
lic policy. The age of alcohol onset was also early in our c-SLE
patients (14 years), different from a national survey performed
in Brazilian adolescents (15.8 years).14
In contrast to alcohol intake, smoking and marihuana were
rarely used by lupus and healthy adolescents, probably due to
the predominance of females. Indeed, male gender was asso-
ciated with an increased risk for illegal drug use.14 The illicit
or licit drug use did not inﬂuence sexual function parameters
and contraceptive use, differently from another study.3 These
substances seemed not to interfere with disease markers and
treatments in c-SLE patients.
Importantly, our study showed a low risk for problem-
atic/hazardous substance pattern of use in c-SLE patients,
probably due to complex disease and overprotection by
parents and families. However, adolescent experimentation
has a potential risk for later development of substance
use disorders in adulthood.16 Therefore, prevention is a
more  cost-effective intervention than curative approaches.
Indeed, American Academy of Pediatrics recommends that
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Table 1 – Demographic data, puberty markers, sexual function, alcohol, smoking and illicit drug use, and bullying in
childhood-onset systemic lupus erythematosus (c-SLE) and controls.
Variables c-SLE (n = 34) Healthy controls (n = 35) p
Demographic data
Current age, yrs 15  (12–18) 15 (12–18) 0.563
Female gender 26 (76) 26 (74) 0.833
BMI, kg/m2 22.11 (16.4–36.6) 19.53 (16.4–25.9) 0.002
Social economic class B and C 32 (94) 34 (97) 0.614
Education, yrs 9 (6–12) 10 (6–12) 0.516
Puberty markers
Tanner 3 4 (12) 4 (11) 1.000
Tanner 4–5 27 (79) 31 (89) 0.299
Menarche 24/26 (92) 26/26 (100) 0.490
Menarche age, yrs 12 (10–15) 11.5 (9–15) 0.041
Lupus before menarche, yrs 13 (12–15) 11.5 (9–15) 0.007
Lupus after menarche, yrs 12 (10–14) 11.5 (9–15) 0.595
Spermarche 5/8 (62) 7/9 (78) 0.620
Spermarche age, yrs 12 (12–13) 13 (12–14) 0.240
Lupus before spermarche, yrs 12 (12–13) 13 (12–14) 0.257
Lupus after spermarche, yrs 12.5 (12–13) 13 (12–14) 0.513
Sexual function
Sexual activity 7 (21) 9 (26) 0.614
First sexual activity age, yrs 15.5 (14–17) 15 (12–17) 0.427
Sexual intercourse in last month 1/7 (14) 4/9 (44) 0.308
Condom at the ﬁrst sexual activity 6/7 (86) 8/9 (89) 1.000
Oral contraception use in females 1/6 (17) 3/10a (30) 1.000
Emergency contraceptive use 2/6 (33) 4/9 (44) 1.000
Knowledge of sexual activity by parents 2/7 (29) 6/8 (75) 0.132
Sexual partner in life, number 1 (1–2) 1 (1–2) 0.529
Alcohol, smoking and/or illicit drug use 13  (38) 16 (46) 0.628
Alcohol use 13 (38) 16 (46) 0.628
Age at onset alcohol 14 (10–17) 14 (7–18) 0.887
Drinking alcohol in past 30 days, number 0 (0–2) 0 (0–5) 0.242
Tobacco smoking use 1 (3) 5 (14) 0.198
Age at onset smoking 11 15 (7–15) –
Smoking in past 30 days, number 0 0 (0–30) –
Illicit drug use 0 2 (6) 1.000
Age at onset illicit drug 0 14 (14–14) –
Illicit drug use in past 30 days, number 0 1.5 (0–3) –
CRAFFT score (0–6) 0 (0–1) 0 (0–5) 0.721
CRAFFT score ≥2 0 5 (15) 0.053
CRAFFT item
Car 8 (24) 5 (15) 0.355
Relax 1 (14) 2 (18) 1.000
Alone 0 1 (9) 1.000
Forget 0 5 (45) 0.101
Friends 0 5 (45) 0.101
Trouble 0 0 1.000
Bullying 13/30 (43) 15/34 (44) 0.950
The results are presented in n (%) and median (range).
CRAFFT, car, relax, alone, forget, friends, trouble; screening test.
a One healthy control used oral contraception before sexual activity.
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dolescents be screened for both high-risk sexual behavior,
s well as for drugs and alcohol use as part of routine visit.17
Of note, bullying is unwished, repeated and aggressive
ehavior in school adolescents that involves a real or perceived
ower imbalance. Adolescents with chronic diseases have an
ncreased risk of peer victimization, reinforcing the relevance
f the quality of an inclusive education system.4 Furthermore,
ullying may cause higher rates of depression and anxiety,18
nd may inﬂuence adherence in patients.19 Future prospective
tudy, recruiting larger sample and evaluating these aspects,
ill be necessary in c-SLE population.
We  have conﬁrmed our previous observations of late
enarche age20,21 and normal spermarche age22 in c-
LE patients compared with healthy Brazilian adolescents.
ndocrine-disrupting effects of alcohol and smoking use may
nﬂuence pubertal development,23 however this aspect was
ot evidenced in the present study.
In conclusion, this study showed high frequencies of early
lcohol use in lupus adolescents and healthy controls, with
 possible low risk for substance abuse/dependence in c-SLE
atients. Therefore, our study emphasized a routine screening
or substance use in all c-SLE adolescents.24
unding
his study was supported by grants from Fundac¸ão de Amparo
 Pesquisa do Estado de São Paulo (FAPESP 2011/12471-2 to
AS), Conselho Nacional de Desenvolvimento Cientíﬁco e
ecnológico (CNPq 303422/2015-7 - 1A to CAS), Federico Foun-
ation (to CAS), and Núcleo de Apoio à Pesquisa “Saúde da
rianc¸a e do Adolescente” da USP (NAP-CriAd) to CAS.
onﬂict  of  interests
he authors declare no conﬂict of interests.
cknowledgements
ur gratitude to Ulysses Doria-Filho for the statistical analysis.
e thank Dr. J.R. Knight and Dr. P. Schram of Boston Children’s
ospital, Mass, USA, for supplying the Portuguese version of
RAFFT screen (CEASER) instrument.
 e  f  e  r  e  n  c  e  s
1. Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus
erythematosus with onset before adulthood. Arthritis Care
Res  (Hoboken). 2012;64:1787–93.
2. Atilola O, Stevanovic D, Balhara YP, Avicenna M, Kandemir H,
Knez R, et al. Role of personal and family factors in alcohol
and substance use among adolescents: an international study
with focus on developing countries. J Psychiatr Ment Health
Nurs. 2014;21:609–17.
3. Mialon A, Berchtold A, Michaud PA, Gmel G, Suris JC. Sexual
dysfunctions among young men: prevalence and associated
factors. J Adolesc Health. 2012;51:25–31.
2 6;5 6(3):228–234 233
4. Sentenac M, Gavin A, Gabhainn SN, Molcho M,  Due P,
Ravens-Sieberer U, et al. Peer victimization and subjective
health among students reporting disability or chronic illness
in  11 Western countries. Eur J Public Health. 2013;23:421–6.
5. Hochberg MC. Updating the American College of
Rheumatology revised criteria for the classiﬁcation of
systemic lupus erythematosus. Arthritis Rheum. 1997;
40:1725.
6. Knight JR, Schram P. Portuguese version of CRAFFT screen
(CEASER); 2014. Available at: http://www.ceasar-boston.org/
CRAFFT/pdf/CRAFFT Portuguese.pdf [accessed 17.07.14].
7.  Knight JR, Sherritt L, Shrier LA, Harris SK, Chang G. Validity of
the CRAFFT substance abuse screening test among adolescent
clinic patients. Arch Pediatr Adolesc Med. 2002;156:
607–14.
8. ABEP (Associac¸a˜o Brasileira de Empresas de Pesquisa) 2008.
Available at: www.abep.org – abep@abep.org [accessed
17.07.14].
9.  Marshall JC, Tanner JM. Variations in patterns of pubertal
changes in boys and girls. Arch Dis Child. 1970;45:
13–23.
0. Gladman DD, Iban˜ez D, Urowitz MB. Systemic lupus
erythematosus disease activity index 2000. J Rheumatol.
2002;29:288–91.
1. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz
M, et al. The development and initial validation of the
Systemic Lupus International Collaborating Clinics/American
College of Rheumatology damage index for systemic lupus
erythematosus. Arthritis Rheum. 1996;39:363–9.
2. Menezes AH, Dalmas JC, Scarinci IC, Maciel SM, Cardelli AA.
Factors associated with regular cigarette smoking by
adolescents from public schools in Londrina, Paraná, Brazil.
Cad Saude Publica. 2014;30:774–84.
3. Patrick ME, Wightman P, Schoeni RF, Schulenberg JE.
Socioeconomic status and substance use among young
adults: a comparison across constructs and drugs. J Stud
Alcohol Drugs. 2012;73:772–82.
4. Madruga CS, Laranjeira R, Caetano R, Pinsky I, Zaleski M,  Ferri
CP.  Use of licit and illicit substances among adolescents in
Brazil – a national survey. Addict Behav. 2012;37:
1171–5.
5. Tippett N, Wolke D. Socioeconomic status and bullying:
a  meta-analysis. Am J Public Health. 2014;104:
e48–59.
6. Barbosa Filho VC, Campos WD, Lopes Ada S. Prevalence of
alcohol and tobacco use among Brazilian adolescents: a
systematic review. Rev Saude Publica. 2012;46:
901–17.
7. Levy SJ, Kokotailo PK, Committee on Substance Abuse.
Substance use screening, brief intervention, and referral to
treatment for pediatricians. Pediatrics. 2011;128:
e1330–40.
8. Calvete E. Emotional abuse as a predictor of early
maladaptive schemas in adolescents: contributions to the
development of depressive and social anxiety symptoms.
Child Abuse Negl. 2014;38:735–46.
9. Julian LJ, Yelin E, Yazdany J, Panopalis P, Trupin L, Criswell LA,
et  al. Depression, medication adherence, and service
utilization in systemic lupus erythematosus. Arthritis
Rheum. 2009;61:240–6.
0. Febronio MV, Pereira RM, Bonfa E, Takiuti AD,  Pereyra EA,
Silva CA, et al. Inﬂammatory cervicovaginal cytology is
associated with disease activity in juvenile systemic lupus
erythematosus. Lupus. 2007;16:430–5.
1. Rygg M, Pistorio A, Ravelli A, Maghnie M, Di Iorgi N,
Bader-Meunier B, et al. A longitudinal PRINTO study on
growth and puberty in juvenile systemic lupus
erythematosus. Ann Rheum Dis. 2012;71:511–7.
 o l . 2
2
2234  r e v b r a s r e u m a t
2. Vecchi AP, Borba EF, Bonfá E, Cocuzza M, Pieri P, Kim CA, et al.
Penile anthropometry in systemic lupus erythematosus
patients. Lupus. 2011;20:512–8.
3. Peck JD, Peck BM, Skaggs VJ, Fukushima M, Kaplan HB.
Socio-environmental factors associated with pubertal
development in female adolescents: the role of prepubertal
2 0 1 6;5 6(3):228–234
tobacco and alcohol use. J Adolesc Health. 2011;48:
241–6.4. Britto MT, Rosenthal SL, Taylor J, Passo MH. Improving
rheumatologists’ screening for alcohol use and sexual
activity. Arch Pediatr Adolesc Med. 2000;154:
478–83.
